PCS
BCRX icon

Personal CFO Solutions’s BioCryst Pharmaceuticals BCRX Stock Holding History

Personal CFO Solutions’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
21,926
+259
+1% +$2.34K 0.03% 496
2026
Q1 		$206K Sell
21,667
-40,733
-65% -$316K 0.03% 502
2025
Q4 		$487K Buy
62,400
+212
+0.3% +$1.53K 0.08% 242
2025
Q3 		$472K Hold
62,188
– – 0.08% 240
2025
Q2 		$557K Hold
62,188
– – 0.1% 198
2025
Q1 		$466K Buy
62,188
+672
+1% +$5.42K 0.09% 218
2024
Q4 		$463K Sell
61,516
-215
-0.3% -$1.63K 0.09% 219
2024
Q3 		$469K Hold
61,731
– – 0.07% 278
2024
Q2 		$381K Sell
61,731
-5,000
-7% -$27.6K 0.06% 315
2024
Q1 		$339K Buy
66,731
+428
+0.6% +$2.41K 0.05% 361
2023
Q4 		$397K Sell
66,303
-453
-0.7% -$2.63K 0.07% 293
2023
Q3 		$473K Hold
66,756
– – 0.09% 205
2023
Q2 		$470K Sell
66,756
-1,000
-1% -$8.03K 0.1% 214
2023
Q1 		$565K Buy
67,756
+366
+0.5% +$3.52K 0.12% 172
2022
Q4 		$774K Hold
67,390
– – 0.16% 118
2022
Q3 		$849K Buy
67,390
+302
+0.5% +$3.89K 0.21% 88
2022
Q2 		$710K Sell
67,088
-42,100
-39% -$434K 0.17% 109
2022
Q1 		$1.77M Hold
109,188
– – 0.35% 48
2021
Q4 		$1.51M Hold
109,188
– – 0.28% 64
2021
Q3 		$1.57M Sell
109,188
-2,490
-2% -$39.3K 0.32% 58
2021
Q2 		$1.77M Sell
111,678
-10,000
-8% -$136K 0.36% 54
2021
Q1 		$1.24M Buy
121,678
+16,500
+16% +$170K 0.27% 73
2020
Q4 		$784K Buy
105,178
+14,000
+15% +$72.2K 0.19% 106
2020
Q3 		$0 Buy
91,178
+8,500
+10% +$36.4K ﹤0.01% 155
2020
Q2 		$394K Sell
82,678
-4,400
-5% -$17.6K 0.12% 164
2020
Q1 		$174K Buy
87,078
+55,078
+172% +$152K 0.06% 249
2019
Q4 		$110K Buy
+32,000
New +$80.5K 0.03% 330

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Personal CFO Solutions's BCRX Position: Q2 2026 in Review

Personal CFO Solutions increased its BioCryst Pharmaceuticals (BCRX) stake by 1.2% in Q2 2026, buying an estimated $2.34K and bringing the position to 21,926 shares worth $219K. The position accounts for 0.03% of the portfolio, ranked #496.

Personal CFO Solutions first reported a position in BCRX in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.77M in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Personal CFO Solutions held 21,926 shares of BioCryst Pharmaceuticals worth $219K as of Q2 2026.
  • Personal CFO Solutions bought 259 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.34K.
  • BioCryst Pharmaceuticals made up 0.03% of Personal CFO Solutions's portfolio in Q2 2026, its #496 holding.
  • Personal CFO Solutions first reported a position in BioCryst Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Personal CFO Solutions's BioCryst Pharmaceuticals position peaked at $1.77M in Q1 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Personal CFO Solutions's 13F filing for Q2 2026, filed 7 Aug 2026.